BiotechTube
GAIA BioMedicine

GAIA BioMedicine

Fukuoka, Japan· Est.

A biotech company developing off-the-shelf, non-genetically modified NK-like cell therapies to eliminate solid tumors.

gaia-biomed.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

A biotech company developing off-the-shelf, non-genetically modified NK-like cell therapies to eliminate solid tumors.

Oncology

Technology Platform

GAIA NK-like cell platform produces off-the-shelf, non-genetically modified allogeneic cells with enhanced tumor infiltration. The GAAAP peptide platform arms these cells with antibodies for targeted tumor killing while reducing off-tumor toxicity.

Opportunities

The primary opportunity is establishing a safe and effective off-the-shelf cell therapy for multiple solid tumor types, a vast market poorly addressed by current autologous CAR-T therapies.
The GAAAP platform also allows for rapid generation of new antibody-armed candidates against various targets.

Risk Factors

Key risks include clinical trial failure, potential unknown toxicities of the platform, and manufacturing/commercialization challenges for allogeneic cell products.
Competition from other NK cell and solid tumor-focused cell therapy developers is intense.

Competitive Landscape

Competes with other allogeneic NK/CAR-NK cell therapy companies (e.g., Nkarta, Fate Therapeutics) and solid tumor-focused cell therapy developers. Differentiation lies in the non-genetically modified NK-like cells with enhanced homing properties and the GAAAP targeting system designed to reduce toxicity.

More companies in Japan →